Neuland Labs Approves Rs 342 Crore Capex To Enhance Capacity Of Two Units
Pharmaceutical company Neuland Laboratories Ltd. has disclosed to the national exchanges through a filing on Tuesday that the company has approved capital expenditure worth Rs 342 crore for two of its units in Telangana.
Amount worth Rs 254 crore from the capex is expected to be utilised for the enhancement of the company's unit located in Bonthapally village with a proposed capacity addition of 6.37 kilolitres, to support development and commercial production of peptides for the company's GDS & CMS business.
This addition is expected to be executed by fiscal 2027. The company plans to fund this capex through debt and internal accruals, as per an exchange filing.
The remaining Rs 88 crore is expected to be used for an addition of 52 kilolitres to the existing 321 kilolitres capacity of the company's Gaddapotharam village unit. This capacity is expected to come online in 15 to 18 months.
Neuland Laboratories is a global active pharmaceutical ingredient contract development and manufacturing organisation. The company works with biotechnology and pharmaceutical firms to help design, develop, and manufacture complex active pharmaceutical ingredients.
The company specialises in developing small molecules and peptides for clinical trials, which is expected to provide seamless scalability from initial stages to full-scale commercial manufacturing.
Shares of Neuland Laboratories closed 4.78% lower at Rs 13,155 apiece on the NSE, compared to a 1.37% decrease in the benchmark Nifty 50.
The stock has risen 134.22% over the past 12 months. Two analysts tracking the company have a 'buy' rating on the stock, according to Bloomberg data. The average of 12-month analysts' consensus price targets implies a potential upside of 36.7%.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
